tert-Butyl (5-formylpyrazin-2-yl)carbamate

Catalog No. :
ACWIYX743
CAS No. :
959617-71-1
Molecular Formula :
C10H13N3O3
Molecular Weight :
223.23

IUPAC Name:tert-butyl (5-formylpyrazin-2-yl)carbamate

tert-Butyl (5-formylpyrazin-2-yl)carbamate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
100mg97%$219.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Nametert-Butyl (5-formylpyrazin-2-yl)carbamate
IUPAC Nametert-butyl (5-formylpyrazin-2-yl)carbamate
MDL No.MFCD09907675
Molecular FormulaC10H13N3O3
Molecular Weight223.23
SMILESCC(C)(C)OC(=O)NC1=CN=C(C=O)C=N1
InChI KeyARENRXTXYPJFQV-UHFFFAOYSA-N
Synonym5-Aminopyrazine-2-carboxaldehyde, 5-BOC protected;tert-Butyl (5-formylpyrazin-2-yl)carbamate, 2-[(tert-Butoxycarbonyl)amino]-5-formylpyrazine;(5-Formyl-pyrazin-2-yl)-carbamic acid tert-butyl ester;tert-butyl N-(5-formylpyrazin-2-yl)carbamate;Carbamic acid, N-(5-formyl-2-pyrazinyl)-, 1,1-dimethylethyl ester
CAS No.959617-71-1
PubChem CID44118835

Safety Data

Pictogram
CorrosiveHarmful or irritant
Signal Word
Danger
Hazard Statement(s)
H302-H315-H318-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P310-P330-P332+P313-P362-P403+P233-P405-P501

Synthetic Route by SureRoute

1. ACWIYX743 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACQNLY675 route compound structure diagram
    ACQNLY675369638-69-7 In Stock
  2. Plus
  3. ACBCRN096 route compound structure diagram
    ACBCRN09622840-91-1 In Stock
  4. Then
  5. ACWIYX743 route product structure diagram
    ACWIYX743959617-71-1
Inquiry

2. ACWIYX743 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACTMWQ847 route compound structure diagram
    ACTMWQ847874476-55-8 In Stock
  2. Then
  3. ACWIYX743 route product structure diagram
    ACWIYX743959617-71-1
Inquiry

Comments (0)